Hamill R W, Markesbery W R, McDaniel K, Coleman P D
Department of Neurology, University of Rochester Medical Center, NY 14620.
Neurobiol Aging. 1993 Nov-Dec;14(6):539-45. doi: 10.1016/0197-4580(93)90037-c.
We review current understanding of the clinical and pathologic information needed for the determination of optimal brain tissue samples for the conduct of studies of Alzheimer's disease (AD). Characteristics that may distinguish AD from other dementing disorders are discussed. Selected considerations in the conduct of basic neurobiological studies are also outlined. Although the 28 NIA-funded Alzheimer's Centers can provide excellent clinical and neuropathological data, studies conducted outside these centers should also strive to gather the information suggested here. Clinical and neuropathological data should be used not only to classify subjects as control or AD, but also as variables that may significantly contribute to the analysis of neurobiological data obtained in the laboratory.
我们回顾了当前对于确定用于阿尔茨海默病(AD)研究的最佳脑组织样本所需临床和病理信息的理解。讨论了可能将AD与其他痴呆症区分开来的特征。还概述了基础神经生物学研究中的一些选定注意事项。尽管28个由美国国立衰老研究所资助的阿尔茨海默病中心能够提供出色的临床和神经病理学数据,但在这些中心之外开展的研究也应努力收集此处建议的信息。临床和神经病理学数据不仅应用于将受试者分类为对照或AD,还应用作可能对实验室获得的神经生物学数据的分析有重大贡献的变量。